To conduct an evaluation before and two years after the introduction of the Pneumococcal conjugate vaccine (PCV) to study the direct and indirect impact of PCV introduction on vaccine-type pneumococcal carriage among healthy Indonesian children under five years of age.

To assess the impact of the Pneumococcal conjugate vaccine catch up campaign among internally displaced populations in the northern Sahel region of Burkina Faso. This effort will implement and evaluate the impact of changing the pneumococcal conjugate vaccine schedule.

To support Centers for Independent Living (CILs) in increasing access to COVID-19 vaccination.

To support a literature review of pneumococcal conjugate vaccines (PCV) dosing schedules and impact assessments to guide discussions about potential changes to current guidance on PCV schedules, an analysis needed to support the WHO Strategic Advisory Group of Experts on Immunization PCV Working Group.

To honor an EIS officer or recent graduate (within five years) for contributions to vaccine-preventable diseases.

To honor CDC's 50th anniversary and the 25th anniversary of the first combination vaccine for measles, mumps and rubella, this award funds an annual lecture at CDC's National Immunization Conference by an individual whose work or leadership has made significant contributions to the elimination of measles, mumps, or rubella or individuals who have contributed to the elimination of any pediatric disease and immunization overall.

To evaluate the impact of a pneumococcal conjugate vaccine schedule change in Mozambique on vaccine-type pneumococcal carriage and invasive pneumococcal disease; and serotype 1 colonization among patients with suspected pneumonia and serotype 1 disease among children and adults.

To provide laboratory support for the analysis of immunogenicity and shedding of new oral Poliovirus vaccines in human clinical trials and related issues for polio endgame.

To ensure impact and effectiveness of rotavirus vaccines and sustain vaccine use by policy makers, physicians and parents to increase the speed of adoption of vaccine by other countries in Africa and around the world.

To evaluate the impact of HPV vaccine and the persistence of HPV antibody among HPV-vaccinated women living with HIV in Botswana.

To help implement the CDC Foundation programs and activities supporting the Targeted Country Assistance portion of the 2022-2025 Partners’ Engagement Framework.

To show the health impact of low-cost, Indian-made rotavirus vaccines in high burden, low-income countries of Africa and Asia.

To support the chemistry, manufacturing and control (CMC) and preclinical development of an inactivated rotavirus vaccine.